期刊:Science [American Association for the Advancement of Science] 日期:2019-06-13卷期号:364 (6445): 1043.11-1045
标识
DOI:10.1126/science.364.6445.1043-k
摘要
Microbiota
The efficacy of l-dopa treatment for Parkinson's disease is hugely variable between individuals, depending on the composition of their microbiota. l-Dopa is decarboxylated into active dopamine, but if the gut microbiota metabolize l-dopa before it crosses the blood-brain barrier, medication is ineffective. Maini Rekdal et al. found that different species of bacterium are involved in l-dopa metabolism (see the Perspective by O'Neill). Tyrosine decarboxylase (TDC) from Enterococcus faecalis and dopamine dehydroxylase (Dadh) from Eggerthella lenta A2 sequentially metabolized l-dopa into m -tyramine. The microbial l-dopa decarboxylase can be inactivated by ( S )-α-fluoromethyltyrosine (AFMT), which indicates possibilities for developing combinations of Parkinson's drugs to circumvent microbial inactivation.
Science , this issue p. [eaau6323][1]; see also p. [1030][2]
[1]: /lookup/doi/10.1126/science.aau6323
[2]: /lookup/doi/10.1126/science.aax8937